Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02947685 |
Recruitment Status :
Active, not recruiting
First Posted : October 28, 2016
Last Update Posted : January 30, 2024
|
Sponsor:
Alliance Foundation Trials, LLC.
Collaborators:
Pfizer
German Breast Group
Fondazione Michelangelo
PrECOG, LLC.
Breast Cancer Trials, Australia and New Zealand
Syneos Health
SOLTI Breast Cancer Research Group
UNICANCER
Information provided by (Responsible Party):
Alliance Foundation Trials, LLC.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | April 30, 2024 |
Estimated Study Completion Date : | July 31, 2026 |
Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Finn, R.S., et al., PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breast cancer (ABC). ASCO Meeting Abstracts, 2016. 34(15_suppl): p. 507.
Pfizer, Inc. Palbociclib (PD-0332991): Investigator's Brochure. N.p.: Pfizer, 2015. Print.
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):